Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
about
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsImaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast CancerDevelopment of Companion DiagnosticsAdvances in molecular imaging for breast cancer detection and characterizationRole of positron emission tomography for the monitoring of response to therapy in breast cancerOptimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals.GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding.The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.Longitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy.Pharmacodynamic imaging guides dosing of a selective estrogen receptor degraderFeasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target.Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging.Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response.IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.Failed PET Application Attempts in the Past, Can We Avoid Them in the Future?Beyond Correlations, Sensitivities, and Specificities: Case Examples of the Evaluation of Advanced Imaging in Oncology Clinical Trials and Cancer Treatment.Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.Meeting the challenges of PET-based molecular imaging in cancer.18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxelFulvestrant and male breast cancer: a pooled analysis.18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer.Therapy monitoring of skeletal metastases with whole-body diffusion MRI.Effect of anti-PMSG on distribution of estrogen receptor alpha and progesterone receptor in mouse ovary, oviduct and uterus.Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.
P2860
Q26740567-CE3D6A5B-1FCF-4AF7-9B20-FF5DDE774951Q26772868-6085C7CB-5FCE-41E3-8999-A71E7ACFD955Q26774670-20BF597E-1F21-4C49-A53C-09DD2ADAC76BQ27000462-C90BDC8C-4DCC-4CC4-9407-8013CD1D3D39Q28080621-74A6EDDA-D065-4EE4-BF08-84B3486C6FA4Q34068083-26208CA8-78A5-40A4-A580-482C5839B856Q34518285-A29792E8-CDD7-4410-A9E1-89E6A6531E35Q34534031-4357D9DE-B2A6-4B7B-A26F-BF6F2D42C4EAQ35143049-B9CB2C3A-CB1F-4404-A164-6DE21312411FQ35178385-0CFEB99D-148A-4355-AA1A-3278FA2E6B0BQ35502637-4BF715D3-E9C4-4126-8FD5-AB712CB2676FQ36301166-F5689C80-4323-410F-87F7-A0B52671A9DDQ36344573-B372FC13-6216-4831-8D44-9396B7CE2B4DQ36429530-63A6A2BA-0495-4C43-B4FB-E557C0699D68Q37641611-D90A4CBA-0165-49AC-9DA1-D32268E9A513Q38090509-024DCC02-5DC9-4F42-8F3A-D27D0D74C6B4Q38631164-94A63D14-B2AC-4935-8B2B-6B0C2D02FCAEQ38800009-57100B5A-02A3-497B-AC62-9F13955F18E1Q38836364-BDD45590-0380-4D9C-9B0E-5EDD0EC05DFCQ39160175-AE3DD569-D43D-4483-A49D-637D8DB175BBQ39345390-4AC3E401-E7D6-419D-89FA-CB6C824CA2D6Q40409656-3DF3A99E-0650-4BCD-91D8-EF47E63AD3A8Q41140406-73CAD953-531D-436F-A0BB-ADBA42EB5D9EQ41677482-E4E1D555-DB28-45D2-B340-50F34B55811BQ47732227-B9EADECA-44A2-41F9-AA4D-695B8BACD301Q51114179-F16DA57B-BD28-4534-A0DA-CC1927485A76Q51116267-8BBF0F36-A04A-4C9B-AF86-7562C2690E2FQ51311647-0ADAA92C-AEC6-4BEC-8CBE-02369E393051
P2860
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Fluoroestradiol positron emiss ...... with metastatic breast cancer.
@ast
Fluoroestradiol positron emiss ...... with metastatic breast cancer.
@en
type
label
Fluoroestradiol positron emiss ...... with metastatic breast cancer.
@ast
Fluoroestradiol positron emiss ...... with metastatic breast cancer.
@en
prefLabel
Fluoroestradiol positron emiss ...... with metastatic breast cancer.
@ast
Fluoroestradiol positron emiss ...... with metastatic breast cancer.
@en
P2093
P2860
P1476
Fluoroestradiol positron emiss ...... with metastatic breast cancer.
@en
P2093
Brenda F Kurland
David A Mankoff
Erin K Schubert
Georgiana K Ellis
Hannah M Linden
Jeanne M Link
Jennifer M Specht
Julie R Gralow
Kenneth A Krohn
Lanell M Peterson
P2860
P304
P356
10.1158/1078-0432.CCR-10-3321
P407
P577
2011-07-12T00:00:00Z